In the published article, there was an error in the author list, and authors Boglarka Ujhazi, Sumai Gordon, and Krisztian Csomos were erroneously excluded. In addition, their author contributions statement has been updated. The corrected statement reads as follows:
JM - manuscript write up, data collection, patient interview. AR - manuscript write up, literature review. RC - manuscript write up. ME - clinical research coordination. TG - pharmacy in gynecology clinic. CD, KC, BU, and SG - immunologic evaluation. AC - control of infectious diseases. CSo - control of infectious diseases. CSr - control of pulmonary infections. JD - manuscript write up, immunologic evaluation, literature review. TH - early treating immunologist, primary diagnosis with IEI. RI-K - treating oncologist. JW - currently treating immunologist, primary investigator. All authors contributed to the article and approved the submitted version.
The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Summary
Keywords
antibody deficiency, primary immunodeficiency, ovarian cancer, case report, inborn error of immunity
Citation
Mammadova J, Redden A, Cruz R, Ujhazi B, Gordon S, Ellison M, Gatewood T, Duff C, Cannella A, Somboonwit C, Sriaroon C, Csomos K, Dasso JF, Harville T, Ismail-Khan R and Walter JE (2022) Corrigendum: Case report: Initial treatment adjustments and complications in ovarian cancer patient with inborn error of immunity. Front. Oncol. 12:1007616. doi: 10.3389/fonc.2022.1007616
Received
30 July 2022
Accepted
17 August 2022
Published
22 September 2022
Approved by
Frontiers Editorial Office, Frontiers Media SA, Switzerland
Volume
12 - 2022
Updates
Copyright
© 2022 Mammadova, Redden, Cruz, Ujhazi, Gordon, Ellison, Gatewood, Duff, Cannella, Somboonwit, Sriaroon, Csomos, Dasso, Harville, Ismail-Khan and Walter.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Jamila Mammadova, jmammadova@usf.edu
This article was submitted to Pharmacology of Anti-Cancer Drugs, a section of the journal Frontiers in Oncology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.